Evaluation of host immune responses to pulmonary cryptococcosis using a temperature-sensitive C. neoformans calcineurin A mutant strain.
Cryptococcus neoformans is an opportunistic fungal pathogen that threatens individuals with impaired cell-mediated immunity (CMI). Presently, there are no standardized vaccines available to prevent cryptococcal infections and conventional anti-fungal drug therapy does not induce host immune reactivity and thus cannot efficiently resolve C. neoformans infections in immunocompromised individuals. The present study was designed to characterize pulmonary immune responses following infection with an avirulent temperature-sensitive (ts) mutant, calcineurin A1 (cna1) compared to the pathogenic C. neoformans strain H99 and its potential to induce protective anti-cryptococcal immunity. Host CMI responses in cna1-inoculated mice were observed to be dose-dependent, and comprise increases in pulmonary macrophages and CD4(+) T lymphocytes. However, cytokine analysis demonstrated a mixed pulmonary cytokine response (increases in IL-4, and MCP-1) with no induction of IFN-gamma. Also, pre-immunization with the ts cna1 mutant did not result in protection from a subsequent secondary pulmonary infection with the pathogenic C. neoformans strain H99. Taken together, these results suggest that host pulmonary CMI responses to the ts cna1 mutant that is eventually eliminated from the host without the induction of IFN-gamma appear to be dose-dependent, diverse, and require further stimulation to induce C. neoformans-specific Th1-type cytokine responses to resolve subsequent experimental pulmonary cryptococcal infections.
Wormley
Floyd L
FL
Department of Medicine/Division of Infectious Diseases, Duke University Medical Center, Duke South, Stead Bldg, Box 3353, Durham, NC 27710, USA. floyd.wormley@duke.edu
Cox
Gary M
GM
Perfect
John R
JR
D000818:Animals; D015496:CD4-Positive T-Lymphocytes / Q000276:immunology; D019703:Calcineurin / Q000235:genetics*; D018932:Chemokine CCL2 / Q000032:analysis; D003453:Cryptococcosis / Q000276:immunology* / Q000382:microbiology / Q000473:pathology; D003455:Cryptococcus neoformans / Q000235:genetics* / Q000276:immunology* / Q000472:pathogenicity; D004195:Disease Models, Animal; D005260:Female; D005657:Fungal Vaccines / Q000276:immunology; D007111:Immunity, Cellular; D007371:Interferon-gamma / Q000032:analysis; D015847:Interleukin-4 / Q000032:analysis; D008168:Lung / Q000276:immunology* / Q000382:microbiology / Q000473:pathology; D008172:Lung Diseases, Fungal / Q000276:immunology* / Q000382:microbiology / Q000473:pathology; D008264:Macrophages / Q000276:immunology; D051379:Mice; D009154:Mutation; D014613:Vaccines, Attenuated / Q000276:immunology
C491768:Ccl2 protein, mouse; D018932:Chemokine CCL2; D005657:Fungal Vaccines; D014613:Vaccines, Attenuated; D015847:Interleukin-4; D007371:Interferon-gamma; D019703:Calcineurin